Aripiprazole/sertraline
| Combination of | |
|---|---|
| Aripiprazole | Atypical antipsychotic |
| Sertraline | Selective serotonin reuptake inhibitor |
| Clinical data | |
| Other names | ASC-01 |
| Routes of administration | By mouth |
| Legal status | |
| Legal status | |
Aripiprazole/sertraline (developmental code name ASC-01) is a combination formulation of aripiprazole (Abilify), an atypical antipsychotic, and sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), which is under development by Otsuka Pharmaceutical for the treatment of major depressive disorder (MDD).[1] It combines serotonin reuptake inhibition from sertraline and modulation of dopamine and serotonin receptors from aripiprazole.[1] In July 2017, it was in preregistration in Japan for the treatment of MDD.[1]
See also
References
- 1 2 3 "Aripiprazole/sertraline - Otsuka Pharmaceutical". AdisInsight. Springer Nature Switzerland AG.
| D1-like |
| ||||||
|---|---|---|---|---|---|---|---|
| D2-like |
| ||||||
| |||||||
| DAT (DRIs) |
| ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NET (NRIs) |
| ||||||||||||||
| SERT (SRIs) |
| ||||||||||||||
| VMATs |
| ||||||||||||||
| Others |
| ||||||||||||||
See also: Receptor/signaling modulators • Monoamine releasing agents • Adrenergics • Dopaminergics • Serotonergics • Monoamine metabolism modulators • Monoamine neurotoxins | |||||||||||||||
Serotonin receptor modulators | |||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5-HT1 |
| ||||||||||||||||||||||||||||||||||||||
| 5-HT2 |
| ||||||||||||||||||||||||||||||||||||||
| 5-HT3–7 |
| ||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.